Co-Delivery of Docetaxel and Curcumin Functionalized Mixed Micelles for the Treatment of Drug-Resistant Breast Cancer by Oral Administration

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2024 Aug 27

PMID 39188859

Authors

Chengyang Dian

Zebin Qian

Mengnan Ran

Xiong Yan

Linghui Dian

Affiliations

Soon will be listed here.

Abstract

Background: Chemotherapeutic drugs have some drawbacks in antineoplastic therapy, mainly containing seriously toxic side effects caused by injection and multi-drug resistance (MDR). Co-delivery with two or more drugs via nanomicelles is a promising strategy to solve these problems. Oral chemotherapy is increasingly preferred owing to its potential to enhance the life quality of patients.

Methods And Results: The study intended to develop mixed micelles using D-α-Tocopherol poly(ethylene glycol) 1000 succinate (TPGS) and soluplus for the co-encapsulation of docetaxel (DTX) and curcumin (CUR), marked as (DTX+CUR)-loaded mixed micelles, treating drug-resistant breast cancer by oral administration. The (DTX+CUR)-loaded mixed micelles had a uniform particle size (~64 nm), high drug loading and encapsulation efficiency, in vitro sustained-release properties and good pH-dependent stability. In vitro cell study, the (DTX+CUR)-loaded mixed micelles displayed the highest cellular uptake, cytotoxicity, cell apoptosis-inducing rates and cell ROS-inducing levels on MCF-7/Adr cells. Notably, in vivo pharmacokinetic studies, (DTX+CUR)-loaded mixed micelles enhanced markedly the oral absorption of DTX compared to pure DTX, with a relative oral bioavailability of 574%. The (DTX+CUR)-loaded mixed micelles by oral administration had the same anticancer efficacy as taxotere by injection in resistant breast cancer bearing mice.

Conclusion: (DTX+CUR)-loaded mixed micelles could provide a potential formulation for treating drug-resistant breast cancers by oral administration.

Citing Articles

Soluplus-Based Pharmaceutical Formulations: Recent Advances in Drug Delivery and Biomedical Applications.

Guembe-Michel N, Nguewa P, Gonzalez-Gaitano G Int J Mol Sci. 2025; 26(4).

PMID: 40003966 PMC: 11855892. DOI: 10.3390/ijms26041499.

References

Mei L, Zhang Z, Zhao L, Huang L, Yang X, Tang J . Pharmaceutical nanotechnology for oral delivery of anticancer drugs. Adv Drug Deliv Rev. 2012; 65(6):880-90. DOI: 10.1016/j.addr.2012.11.005. View

Ferro Y, Maurotti S, Tarsitano M, Lodari O, Pujia R, Mazza E . Therapeutic Fasting in Reducing Chemotherapy Side Effects in Cancer Patients: A Systematic Review and Meta-Analysis. Nutrients. 2023; 15(12). PMC: 10303481. DOI: 10.3390/nu15122666. View

Guo Y, Luo J, Tan S, Otieno B, Zhang Z . The applications of Vitamin E TPGS in drug delivery. Eur J Pharm Sci. 2013; 49(2):175-86. DOI: 10.1016/j.ejps.2013.02.006. View

Ipar V, DSouza A, Devarajan P . Enhancing Curcumin Oral Bioavailability Through Nanoformulations. Eur J Drug Metab Pharmacokinet. 2019; 44(4):459-480. DOI: 10.1007/s13318-019-00545-z. View

Patel H, Shaikh S, Ray D, Aswal V, Vaidya F, Pathak C . Formulation, Solubilization, and In Vitro Characterization of Quercetin-Incorporated Mixed Micelles of PEO-PPO-PEO Block Copolymers. Appl Biochem Biotechnol. 2021; 194(1):445-463. DOI: 10.1007/s12010-021-03691-w. View

Keyvani-Ghamsari S, Khorsandi K, Gul A . Curcumin effect on cancer cells' multidrug resistance: An update. Phytother Res. 2020; 34(10):2534-2556. DOI: 10.1002/ptr.6703. View

Mehata A, Setia A, Vikas , Malik A, Hassani R, Dailah H . Vitamin E TPGS-Based Nanomedicine, Nanotheranostics, and Targeted Drug Delivery: Past, Present, and Future. Pharmaceutics. 2023; 15(3). PMC: 10054265. DOI: 10.3390/pharmaceutics15030722. View

Zhou S, Shang Q, Wang N, Li Q, Song A, Luan Y . Rational design of a minimalist nanoplatform to maximize immunotherapeutic efficacy: Four birds with one stone. J Control Release. 2020; 328:617-630. DOI: 10.1016/j.jconrel.2020.09.035. View

Wang W, Li M, Wang L, Chen L, Goh B . Curcumin in cancer therapy: Exploring molecular mechanisms and overcoming clinical challenges. Cancer Lett. 2023; 570:216332. DOI: 10.1016/j.canlet.2023.216332. View

10.

Termini D, Den Hartogh D, Jaglanian A, Tsiani E . Curcumin against Prostate Cancer: Current Evidence. Biomolecules. 2020; 10(11). PMC: 7696488. DOI: 10.3390/biom10111536. View

11.

Huang X, Zhou C, Wang H, Chen C, Yu S, Xu Q . Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl-sulfobutyl-β-cyclodextrin inclusion complex. AAPS PharmSciTech. 2011; 12(2):665-72. PMC: 3134670. DOI: 10.1208/s12249-011-9631-0. View

12.

Yao C, Liu J, Wu X, Tai Z, Gao Y, Zhu Q . Reducible self-assembling cationic polypeptide-based micelles mediate co-delivery of doxorubicin and microRNA-34a for androgen-independent prostate cancer therapy. J Control Release. 2016; 232:203-14. DOI: 10.1016/j.jconrel.2016.04.034. View

13.

Gaucher G, Satturwar P, Jones M, Furtos A, Leroux J . Polymeric micelles for oral drug delivery. Eur J Pharm Biopharm. 2010; 76(2):147-58. DOI: 10.1016/j.ejpb.2010.06.007. View

14.

Dian L, Yu E, Chen X, Wen X, Zhang Z, Qin L . Enhancing oral bioavailability of quercetin using novel soluplus polymeric micelles. Nanoscale Res Lett. 2015; 9(1):2406. PMC: 4493852. DOI: 10.1186/1556-276X-9-684. View

15.

Liang C, Bai X, Qi C, Sun Q, Han X, Lan T . Π electron-stabilized polymeric micelles potentiate docetaxel therapy in advanced-stage gastrointestinal cancer. Biomaterials. 2020; 266:120432. PMC: 7611946. DOI: 10.1016/j.biomaterials.2020.120432. View

16.

Kalaria D, Sharma G, Beniwal V, Kumar M . Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm Res. 2008; 26(3):492-501. DOI: 10.1007/s11095-008-9763-4. View

17.

Simoes S, Figueiras A, Veiga F, Concheiro A, Alvarez-Lorenzo C . Polymeric micelles for oral drug administration enabling locoregional and systemic treatments. Expert Opin Drug Deliv. 2014; 12(2):297-318. DOI: 10.1517/17425247.2015.960841. View

18.

Ma W, Guo Q, Li Y, Wang X, Wang J, Tu P . Co-assembly of doxorubicin and curcumin targeted micelles for synergistic delivery and improving anti-tumor efficacy. Eur J Pharm Biopharm. 2016; 112:209-223. DOI: 10.1016/j.ejpb.2016.11.033. View

19.

Hu Y, Zhang J, Luo Q, Xu J, Yan Y, Mu L . Nanostructured Dihydroartemisinin Plus Epirubicin Liposomes Enhance Treatment Efficacy of Breast Cancer by Inducing Autophagy and Apoptosis. Nanomaterials (Basel). 2018; 8(10). PMC: 6215314. DOI: 10.3390/nano8100804. View

20.

Qi S, Sun J, Yu H, Yu S . Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug Deliv. 2017; 24(1):1909-1926. PMC: 8241150. DOI: 10.1080/10717544.2017.1410256. View